This study provides experimental evidence for the inhibitory effect of the WBT formula against inflammatory response by inactivating the TLR4/MyD88/NF-κB pathway, which could be a potential mechanism of the WBT formula treatment for IPF patients (Figure 6). Here, TLR4 is linked to idiopathic pulmonary fibrosis.